<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01569958</url>
  </required_header>
  <id_info>
    <org_study_id>TDCS2011-01</org_study_id>
    <secondary_id>RF-ABR-2007-631680</secondary_id>
    <nct_id>NCT01569958</nct_id>
  </id_info>
  <brief_title>Transcranial Direct Current Stimulation as a Novel Therapeutic Approach in Amyotrophic Lateral Sclerosis</brief_title>
  <official_title>Transcranial Direct Current Stimulation as a Novel Therapeutic Approach in Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Università degli Studi 'G. d'Annunzio' Chieti e Pescara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Catholic University, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministero della Salute, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Università degli Studi 'G. d'Annunzio' Chieti e Pescara</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by
      progressive weakness and muscular atrophy due to the degeneration and loss of motor neurons,
      the nerve cells that, in the central nervous system (motor cortex, brainstem and spinal
      chord), control voluntary movement. Riluzole, the only drug approved for ALS treatment,
      modestly slow disease progression.

      Transcranial direct current stimulation (tDCS) is a noninvasive technique of neuromodulation
      that is currently studied as a possible therapeutic tool for several neurological and
      psychiatric diseases and has been found safe and well tolerated. Based on experimental
      evidence in animals and human subjects, tDCS is expected to reduce motor cortex excitability
      and excitotoxicity, that is neuronal injury induced by excessive glutamatergic stimulation,
      one of postulated pathophysiological mechanisms in ALS.

      This study will investigate if transcranial direct current stimulation of motor cortex is
      useful in delaying disease progression and is well tolerated in ALS patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double blind, randomized, placebo-controlled clinical trial.

      Cathodic tDCS (1 mA for 20 minutes) will be sequentially applied over the motor cortex of
      both sides, for five consecutive days every month for twelve months. The control group will
      receive a sham stimulation that reproduce tactile sensation of real stimulation but has no
      effects on central nervous system. For stimulation, researchers will employ a CE-certified
      medical device acting as a micro-processor-controlled constant current source. All patients
      will take riluzole during the entire period of the study.

      Fifty-four participants will be recruited from three Italian Centers and randomized to one of
      two arms of the study.

      Disease progression and quality of life will be evaluated at baseline and every three months
      during the study.

      At each visit adverse events will be reported and tolerability will be assessed through a
      specific questionnaire.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decline of ALSFRS-R (ALS functional rating scale-revised) from baseline to 12 months</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decline of muscle strength from baseline to 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>A megascore will be obtained by summing scores of single muscles manually tested according to the Medical Research Council Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of upper motor neuron signs from baseline to 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>A score will be obtained based on presence/absence of listed upper motor neuron signs and grade of spasticity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decline of forced vital capacity (percent of predicted normal) from baseline to 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of quality of life from baseline to 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>The ALSAQ-40 questionnaire will be employed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>tDCS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>transcranial direct current stimulation</intervention_name>
    <description>transcranial direct current stimulation applied to the motor cortex of both sides (1 mA, 20 minutes) for five consecutive days every month for 12 months</description>
    <arm_group_label>tDCS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham stimulation</intervention_name>
    <description>1 mA stimulation for 30 seconds every 900 seconds per session</description>
    <arm_group_label>sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of probable, laboratory-supported probable, or definite amyotrophic lateral
             sclerosis according to the El Escorial revised criteria

          -  spinal onset

          -  aged 18 to 85 years inclusive

          -  disease duration ≤ 24 months

          -  disease progression in the past 3 months

          -  FVC ≥ 70% of predicted

          -  score ≥ 2 at the item &quot;swallowing&quot;of the ALS Functional Rating Scale Revised

          -  score ≥ 2 at the item &quot;walking&quot;of the ALS Functional Rating Scale Revised

          -  in treatment with steady regimen of riluzole for a minimum of 1 month before study
             entry, and desiring its continuation

          -  able to give informed consent

          -  written informed consent

        Exclusion Criteria:

          -  bulbar onset

          -  previous poliomyelitis

          -  motor neuron diseases other than ALS

          -  clinical involvement of other neurological systems

          -  pregnancy, lactation,or unwillingness to contraception if required

          -  possible contraindications to tDCS: metals in the head (excluding the mouth);
             electromedical devices; seizures; drugs or neurological conditions lowering seizure
             threshold; alcoholism; severe heart diseases

          -  any severe disease other than ALS

          -  experimental drugs within 1 month prior to enrollment

          -  drugs potentially modifying the response to tDCS
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandra Lugaresi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Università &quot;G. d'Annunzio&quot; di Chieti e Pescara, Dipartimento Neuroscienze ed Imaging, and ASL n. 2 Lanciano-Vasto-Chieti</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro Regionale Malattie Neuromuscolari, Ospedale Clinicizzato &quot;SS. Annunziata&quot;</name>
      <address>
        <city>Chieti</city>
        <zip>66013</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margherita Capasso, MD, PhD</last_name>
      <phone>00390871358585</phone>
      <email>neurolab@unich.it</email>
    </contact>
    <investigator>
      <last_name>Alessandra Lugaresi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margherita Capasso, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Policlinico Università Federico II</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Lucio Santoro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Vincenzo Di Lazzaro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2012</study_first_submitted>
  <study_first_submitted_qc>March 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2012</study_first_posted>
  <last_update_submitted>October 8, 2012</last_update_submitted>
  <last_update_submitted_qc>October 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Università degli Studi 'G. d'Annunzio' Chieti e Pescara</investigator_affiliation>
    <investigator_full_name>Alessandra Lugaresi</investigator_full_name>
    <investigator_title>Prof</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

